Danaher Analysts Cut Their Forecasts After Downbeat Earnings

Danaher Corporation DHR reported weaker-than-expected fourth-quarter earnings on Wednesday.

The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.

The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.

Rainer M. Blair, President and Chief Executive Officer, stated, "Good execution by our team also drove solid cash flow and operating margin expansion."

Danaher said it expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter. However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.

Danaher shares fell 9.7% to close at $223.73 on Wednesday.

These analysts made changes to their price targets on Danaher following earnings announcement.

Barclays analyst Luke Sergott maintained Danaher with an Equal-Weight and lowered the price target from $275 to $240.
Wells Fargo analyst Brandon Couillard maintained Danaher with an Equal-Weight and cut the price target from $280 to $240.

Considering buying DHR stock? Here’s what analysts think: